C07K 16/2815
Against cd8
Official title: {against CD8}
C07K16/2815 (Against cd8) appears on 215 US grants and 471 published applications in this corpus.
Search patents in C07K- Granted patents
- 215
- Published applications
- 471
- Assignees
- 242
- Inventors
- 1,000
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 2 | 0 |
| 1996 | 0 | 0 |
| 1997 | 4 | 0 |
| 1998 | 1 | 0 |
| 1999 | 3 | 0 |
| 2000 | 5 | 0 |
| 2001 | 1 | 3 |
| 2002 | 3 | 7 |
| 2003 | 2 | 13 |
| 2004 | 3 | 4 |
| 2005 | 6 | 8 |
| 2006 | 0 | 4 |
| 2007 | 2 | 2 |
| 2008 | 0 | 2 |
| 2009 | 3 | 5 |
| 2010 | 0 | 2 |
| 2011 | 1 | 6 |
| 2012 | 1 | 3 |
| 2013 | 4 | 7 |
| 2014 | 1 | 11 |
| 2015 | 7 | 7 |
| 2016 | 4 | 15 |
| 2017 | 4 | 16 |
| 2018 | 7 | 22 |
| 2019 | 19 | 41 |
| 2020 | 9 | 38 |
| 2021 | 17 | 36 |
| 2022 | 20 | 48 |
| 2023 | 17 | 42 |
| 2024 | 23 | 47 |
| 2025 | 28 | 39 |
| 2026 | 12 | 43 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Immunostimulatory adjuvants6 Oct 2026US 12,752,000 B2Orionis Biosciences BV
- Compositions and methods for inhibiting T cell exhaustion8 Sep 2026US 12,729,245 B2The Board of Trustees of the Leland Stanford Junior University
- CD8 binding agents and uses thereof25 Aug 2026US 12,715,920 B2Genentech, Inc.
- CD8-specific antibody constructs and compositions thereof7 Jul 2026US 12,674,180 B2Sana Biotechnology, Inc.
- Modular platform for targeted therapeutics30 Jun 2026US 12,668,643 B2Ramot at Tel-Aviv University Ltd.
- Lipid nanoparticles and methods of manufacture and use thereof8 Oct 2026US 2026/0306659 A1Ablynx N. V.
- Heterodimeric Antibodies, Uses in Therapeutic Applications, and Compositions Related Thereto1 Oct 2026US 2026/0297211 A1
- Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof24 Sep 2026US 2026/0285978 A1Janssen Biotech, Inc.
- Multispecific antigen binding proteins and uses thereof10 Sep 2026US 2026/0265376 A1Itabmed Co., Ltd.
- Cd8-specific antibody constructs and compositions thereof10 Sep 2026US 2026/0265780 A1Sana Biotechnology, Inc.
Most cited
By later US patents
- Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells512US 6,352,694 B1Genetics Institute, Inc. · 2002
- Simultaneous stimulation and concentration of cells422US 6,797,514 B2XCYTE Therapies, Inc. · 2004
- Simultaneous stimulation and concentration of cells398US 6,867,041 B2XCYTE Therapies, Inc. · 2005
- Methods of treating HIV infected subjects386US 6,905,680 B2Genetics Institute, Inc. · 2005
- Methods for selectively stimulating proliferation of T cells385US 6,887,466 B2Genetics Institute, Inc. · 2005